Denali Therapeutics
San Francisco, US · 2 known investors
Denali Therapeutics develops therapeutics for neurodegenerative diseases. The company focuses on discovering and developing novel drug candidates targeting specific neurological conditions.
BiotechHealthtechMedical Devices
Investors · 2
In the news
- Will Recent Setbacks Impact Growth Prospects of DNLI Stock?finance.yahoo.com · 2026
- Denali Therapeutics stock hits 52-week high at 25.74 USD By Investing.cominvesting.com · 2026
- Stifel reiterates Buy rating on Denali Therapeutics stock at $41 By Investing.cominvesting.com · 2026
- Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million - Simply Wall St Newssimplywall.st · 2026
- Denali Therapeutics Secures $200 Million Royalty Funding - TipRanks.comtipranks.com · 2026